1
|
Catlin NR, Cappon GD, Davenport SD, Stethem CM, Nowland WS, Campion SN, Bowman CJ. New approach methodologies to confirm developmental toxicity of pharmaceuticals based on weight of evidence. Reprod Toxicol 2024; 129:108686. [PMID: 39128486 DOI: 10.1016/j.reprotox.2024.108686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2024] [Revised: 08/05/2024] [Accepted: 08/08/2024] [Indexed: 08/13/2024]
Abstract
The aim of embryo-fetal developmental toxicity assessments for pharmaceuticals is to inform potential risk of adverse pregnancy outcome, which has traditionally relied on studies in pregnant animals. Recent updates to international safety guidelines (ICH S5R3) have incorporated information on how to use weight of evidence and alternative assays to reduce animal use while still informing risk of fetal harm. Uptake of these alternative approaches has been slow due to limitations in understanding how alternative assays translate to in vivo effects and then relevance to human exposure. To understand the predictivity of new approach methodologies for developmental toxicity (DevTox NAMs), we used two pharmaceutical examples (glasdegib and lorlatinib) to illustrate the value of DevTox NAMs to complement weight of evidence (WoE) assessments while considering the relationship of concentration-effect levels in NAMs to in vivo studies. The in vitro results generated in a battery of assays (mEST, rWEC, zebrafish, and human based stem cells) confirmed the WoE based on literature and further confirmed by preliminary embryo-fetal development data. The data generated for these two compounds supports integrating DevTox NAMs into the developmental toxicity assessment for advanced cancer indications.
Collapse
Affiliation(s)
- Natasha R Catlin
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA.
| | - Gregg D Cappon
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA; Current: ToxStrategies, Katy, TX, USA
| | - Scott D Davenport
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA
| | - Christine M Stethem
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA
| | - William S Nowland
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA
| | - Sarah N Campion
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA
| | - Christopher J Bowman
- Drug Safety Research and Development, Pfizer Research & Development, Groton, CT, USA
| |
Collapse
|
2
|
Chien HT, Roos P, Russel FGM, Theunissen PT, van Meer PJK. The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies. Regul Toxicol Pharmacol 2024; 152:105682. [PMID: 39094967 DOI: 10.1016/j.yrtph.2024.105682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 07/19/2024] [Accepted: 07/30/2024] [Indexed: 08/04/2024]
Abstract
Regulatory guidance for global drug development relies on animal studies to evaluate safety risks for humans, including risk of reproductive toxicity. Weight-of-evidence approaches (WoE) are increasingly becoming acceptable to evaluate risk. A WoE for developmental risk of monoclonal antibodies (mAbs) was evaluated for its ability to retrospectively characterize risk and to determine the need for further in vivo testing based on the remaining uncertainty. Reproductive toxicity studies of 65 mAbs were reviewed and compared to the WoE. Developmental toxicities were absent in 52/65 (80%) mAbs. Lack of toxicity was correctly predicted in 29/52 (56%) cases. False positive and equivocal predictions were made in 9/52 (17%) and 14/52 (27%) cases. For 3/65 (5%) mAbs, the findings were equivocal. Of mAbs with developmental toxicity findings (10/65, 15%), the WoE correctly anticipated pharmacology based reproductive toxicity without any false negative predictions in 9/10 (90%) cases, and in the remaining case (1/10, 10%) an in vivo study was recommended due to equivocal WoE outcome. Therefore, this WoE approach could characterize presence and absence of developmental risk without animal studies. The current WoE could have reduced the need for developmental toxicity studies by 42% without loss of important patient information in the label.
Collapse
Affiliation(s)
- Hsiao-Tzu Chien
- Medicines Evaluation Board, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Puck Roos
- Medicines Evaluation Board, the Netherlands
| | | | - Peter T Theunissen
- Medicines Evaluation Board, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands
| | - Peter J K van Meer
- Medicines Evaluation Board, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|
3
|
Mora-Flores LP, Moreno-Terrazas Casildo R, Fuentes-Cabrera J, Pérez-Vicente HA, de Anda-Jáuregui G, Neri-Torres EE. The Role of Carbohydrate Intake on the Gut Microbiome: A Weight of Evidence Systematic Review. Microorganisms 2023; 11:1728. [PMID: 37512899 PMCID: PMC10385781 DOI: 10.3390/microorganisms11071728] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/12/2023] [Accepted: 06/23/2023] [Indexed: 07/30/2023] Open
Abstract
(1) Background: Carbohydrates are the most important source of nutritional energy for the human body. Carbohydrate digestion, metabolism, and their role in the gut microbiota modulation are the focus of multiple studies. The objective of this weight of evidence systematic review is to investigate the potential relationship between ingested carbohydrates and the gut microbiota composition at different taxonomic levels. (2) Methods: Weight of evidence and information value techniques were used to evaluate the relationship between dietary carbohydrates and the relative abundance of different bacterial taxa in the gut microbiota. (3) Results: The obtained results show that the types of carbohydrates that have a high information value are: soluble fiber with Bacteroides increase, insoluble fiber with Bacteroides and Actinobacteria increase, and Firmicutes decrease. Oligosaccharides with Lactobacillus increase and Enterococcus decrease. Gelatinized starches with Prevotella increase. Starches and resistant starches with Blautia decrease and Firmicutes increase. (4) Conclusions: This work provides, for the first time, an integrative review of the subject by using statistical techniques that have not been previously employed in microbiota reviews.
Collapse
Affiliation(s)
- Lorena P Mora-Flores
- Laboratorio de Biopolímeros, Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
| | - Rubén Moreno-Terrazas Casildo
- Laboratorio de Microbiología, Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
| | - José Fuentes-Cabrera
- Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
| | - Hugo Alexer Pérez-Vicente
- Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
| | - Guillermo de Anda-Jáuregui
- Computational Genomics Division, National Institute of Genomic Medicine, Ciudad de México 14610, Mexico
- Center for Complexity Sciences, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
- Programa de Cátedras CONACYT, Consejo Nacional de Ciencia y Tecnología, Ciudad de México 03940, Mexico
| | - Elier Ekberg Neri-Torres
- Laboratorio de Biopolímeros, Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
- Laboratorio de Microbiología, Departamento de Ingeniería Química, Industrial y de Alimentos-Universidad Iberoamericana Ciudad de México, Ciudad de México 01219, Mexico
| |
Collapse
|
4
|
Papenfuss TL, Himmel L, Kuper CF, Mohanan S, Harleman J, Elmore SA. Toxicologic Pathology Forum: Considerations Regarding Determination of Adversity for Immunopathology Findings in Nonclinical Toxicology Studies with Immune-Modulating Therapeutics. Toxicol Pathol 2023; 51:205-215. [PMID: 37578155 DOI: 10.1177/01926233231190382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
The evaluation of changes in the immune system serves to determine the efficacy and potential immunotoxicologic effects of new products under development. Toxicologic pathologists play critical roles in identifying immune system changes that drive the immunosafety determination. Standard pathology evaluations of therapies and chemicals remain similar; however, biopharmaceutical therapies have moved from simply affecting the immune system to being specifically developed to modify the immune system, which can impact interpretation. Recent explosive growth in immunomodulatory therapies presents a challenge to the toxicologic pathologist, toxicologist, and regulatory reviewer in terms of evaluating the clinical relevance and potential adversity of immune system changes. Beyond the recognition of such changes, there is an increasing expectation to evaluate, describe, and interpret how therapies affect complex immune system pathways for both immunomodulatory therapies and non-immunomodulatory drugs with off-target immunotoxic effects. In this opinion piece, considerations regarding immune system evaluation, the current landscape of immunomodulatory therapies, a brief description of immunotoxicologic (and immunopathologic) endpoints, the importance of integrating such immunosafety data, and relevance to adversity determination are discussed. Importantly, we describe how the current paradigm of determining adversity for immune system changes may be challenging or insufficient and propose a harmonized and flexible approach for assessing adversity.
Collapse
|
5
|
Powell LG, Gillies S, Fernandes TF, Murphy F, Giubilato E, Cazzagon V, Hristozov D, Pizzol L, Blosi M, Costa AL, Prina-Mello A, Bouwmeester H, Sarimveis H, Janer G, Stone V. Developing Integrated Approaches for Testing and Assessment (IATAs) in order to support nanomaterial safety. Nanotoxicology 2022; 16:484-499. [PMID: 35913849 DOI: 10.1080/17435390.2022.2103470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Due to the unique characteristics of nanomaterials (NM) there has been an increase in their use in nanomedicines and innovative medical devices (MD). Although large numbers of NMs have now been developed, comprehensive safety investigations are still lacking. Current gaps in understanding the potential mechanisms of NM-induced toxicity can make it challenging to determine the safety testing necessary to support inclusion of NMs in MD applications. This article provides guidance for implementation of pre-clinical tailored safety assessment strategies with the aim to increase the translation of NMs from bench development to clinical use. Integrated Approaches to Testing and Assessment (IATAs) are a key tool in developing these strategies. IATAs follow an iterative approach to answer a defined question in a specific regulatory context to guide the gathering of relevant information for safety assessment, including existing experimental data, integrated with in silico model predictions where available and appropriate, and/or experimental procedures and protocols for generating new data to fill gaps. This allows NM developers to work toward current guidelines and regulations, while taking NM specific considerations into account. Here, an example IATA for NMs with potential for direct blood contact was developed for the assessment of haemocompatibility. This example IATA brings together the current guidelines for NM safety assessment within a framework that can be used to guide information and data gathering for the safety assessment of intravenously injected NMs. Additionally, the decision framework underpinning this IATA has the potential to be adapted to other testing needs and regulatory contexts.
Collapse
Affiliation(s)
| | - S Gillies
- Heriot-Watt University, Edinburgh, UK
| | | | - F Murphy
- Heriot-Watt University, Edinburgh, UK
| | - E Giubilato
- University Ca' Foscari of Venice, Venice, Italy.,GreenDecision Srl, Venice, Italy
| | - V Cazzagon
- University Ca' Foscari of Venice, Venice, Italy
| | - D Hristozov
- University Ca' Foscari of Venice, Venice, Italy
| | - L Pizzol
- GreenDecision Srl, Venice, Italy
| | - M Blosi
- Institute of Science and Technology for Ceramics, CNR, Italy
| | - A L Costa
- Institute of Science and Technology for Ceramics, CNR, Italy
| | - A Prina-Mello
- Trinity College Dublin, The University of Dublin, Dublin, Ireland
| | - H Bouwmeester
- Division of Toxicology, Wageningen University, Wageningen, The Netherlands
| | - H Sarimveis
- National Technical University of Athens, Athens, Greece
| | - G Janer
- Leitat Technological Centre, Barcelona, Spain
| | - V Stone
- Heriot-Watt University, Edinburgh, UK
| |
Collapse
|
6
|
Ventrella D, Ashkenazi N, Elmi A, Allegaert K, Aniballi C, DeLise A, Devine PJ, Smits A, Steiner L, Forni M, Bouisset-Leonard M, Bacci ML. Animal Models for In Vivo Lactation Studies: Anatomy, Physiology and Milk Compositions in the Most Used Non-Clinical Species: A Contribution from the ConcePTION Project. Animals (Basel) 2021; 11:ani11030714. [PMID: 33808012 PMCID: PMC7998628 DOI: 10.3390/ani11030714] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/01/2021] [Accepted: 03/02/2021] [Indexed: 12/31/2022] Open
Abstract
Simple Summary Nowadays, the importance of breastfeeding has been very well recognized not only by the scientific world but also by public opinion. Such awareness has nonetheless put a lot of pressure on women under chronic pharmacological medication, or that simply need to alleviate common post-partum health issues, due to the lack of scientific data regarding the potential transfer to the offspring during lactation. In such a scenario, the ConcePTION project aims at creating a trusted ecosystem that can efficiently generate and disseminate reliable evidence-based information regarding the effects of medications used during pregnancy and breastfeeding to women and their healthcare providers. Due to the need for a reliable animal species to obtain scientific data, the present review summarizes the main features contributing to the lactation process in the most commonly used laboratory animal species. Abstract The present review aims to summarize the main features of mammary gland anatomy, and the physiology of lactation and colostrum/milk in the most commonly used animal species for regulatory toxicity. The final goal is the selection of a preferred animal species to be enrolled in studies investigating the potential transfer of drugs and exogenous molecules through milk, within the Innovative Medicines Initiative (IMI) funded project ConcePTION. Reference data regarding humans were also collected and analyzed in order to highlight critical similarities and differences with the studied species. Additional practical considerations were also taken into account, such as ethical consideration regarding the chosen species which affects the group size, financial implications and technical feasibility of lactation trials (e.g., ease of sampling, volume of sampling, husbandry requirements and scientific recognition). In conclusion, the present analysis of the literature confirms the complexity of the decisional process behind the choice of an animal model for in vivo trials. For some of the evaluated species, data were either poor or missing, highlighting the necessity to generate more physiological background studies for species that are routinely used in laboratory settings. Overall, when taking into consideration ethical factors, feasible group size, milk volume and ease of milk collection, and physiological similarities with humans, minipigs seem to represent the most appropriate choice.
Collapse
Affiliation(s)
- Domenico Ventrella
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | - Nurit Ashkenazi
- Global Research and Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel; (N.A.); (L.S.)
| | - Alberto Elmi
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
- Correspondence: ; Tel.: +39-051-2097923
| | - Karel Allegaert
- Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; (K.A.); (A.S.)
- Department of Clinical Pharmacology and Pharmacotherapy, KU Leuven, 3000 Leuven, Belgium
- Department of Hospital Pharmacy, Erasmus MC, 3015 GD Rotterdam, The Netherlands
| | - Camilla Aniballi
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | - Anthony DeLise
- Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USA;
| | - Patrick John Devine
- Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA;
| | - Anne Smits
- Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; (K.A.); (A.S.)
- Neonatal Intensive Care Unit, University Hospital Leuven, 3000 Leuven, Belgium
| | - Lilach Steiner
- Global Research and Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel; (N.A.); (L.S.)
| | - Monica Forni
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| | | | - Maria Laura Bacci
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emlia, 40064 Bologna, Italy; (D.V.); (C.A.); (M.F.); (M.L.B.)
| |
Collapse
|
7
|
Catlin NR, Stethem C, Bowman CJ, Campion SN, Nowland WS, Cappon GD. Knockout mouse models are predictive of malformations or embryo-fetal death in drug safety evaluations. Reprod Toxicol 2021; 99:138-143. [PMID: 33065206 DOI: 10.1016/j.reprotox.2020.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Traditionally, understanding potential developmental toxicity from pharmaceutical exposures has been based on the results of ICH guideline studies in two species. However, support is growing for the use of weight of evidence approaches when communicating the risk of developmental toxicity, where the intended pharmacologic mode of action affects fundamental pathways in developmental biology or phenotypic data from genetically modified animals may increasingly be included in the overall assessment. Since some concern surrounds the use of data from knockout (KO) mice to accurately predict the risk for pharmaceutical modulation of a target, a deeper understanding of the relevance and predictivity of adverse developmental effects in KO mice for pharmacological target modulation is needed. To this end, we compared the results of embryo-fetal development (EFD) studies for 86 drugs approved by the FDA from 2017 to 2019 that also had KO mouse data available in the public domain. These comparisons demonstrate that data from KO mouse models are overall highly predictive of malformations or embryo-fetal lethality (MEFL) from EFD studies, but less so of a negative outcome in EFD studies. This information supports the use of embryo-fetal toxicity data in KO models as part of weight of evidence approaches in the communication of developmental toxicity risk of pharmaceutical compounds.
Collapse
|
8
|
Kissner T, Blaich G, Baumann A, Kronenberg S, Hey A, Kiessling A, Schmitt PM, Driessen W, Carrez C, Kramer D, Fretland J, Richter WF, Paehler T, Hopfer U, Rattel B. Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. MAbs 2021; 13:1938796. [PMID: 34241561 PMCID: PMC8274438 DOI: 10.1080/19420862.2021.1938796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 05/27/2021] [Accepted: 05/31/2021] [Indexed: 10/26/2022] Open
Abstract
New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019. The session topics were selected by European BioSafe organization committee members based on recent company achievements, agency interactions and new data obtained in the non-clinical safety testing of biotherapeutics, for which data sharing would be of interest and considered as valuable information. The presented session topics ranged from strategies of in vitro testing, immunogenicity prediction, bioimaging, and developmental and reproductive toxicology (DART) assessments to first-in-human (FIH) dose prediction and bioanalytical challenges, reflecting the entire space of different areas of expertise and different molecular modalities. During the 9th meeting of the European BioSafe members, the following topics were presented and discussed in 6 main sessions (with 3 or 4 presentations per session) and in three small group breakout sessions: 1) DART assessment with biotherapeutics: what did we learn and where to go?; 2) Non-animal testing strategies; 3) Seeing is believing: new frontiers in imaging; 4) Predicting immunogenicity during early drug development: hope or despair?; 5) Challenges in FIH dose projections; and 6) Non-canonical biologics formats: challenges in bioanalytics, PKPD and biotransformation for complex biologics formats. Small group breakout sessions were organized for team discussion about 3 specific topics: 1) Testing of cellular immune function in vitro and in vivo; 2) MABEL approach (toxicology and pharmacokinetic perspective); and 3) mRNA treatments. This workshop report presents the sessions and discussions at the meeting.
Collapse
Affiliation(s)
- Thomas Kissner
- Preclinical Safety, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
| | - Guenter Blaich
- Preclinical Safety, AbbVie Deutschland GmbH, Ludwigshafen, Germany
| | - Andreas Baumann
- R&D Pharmaceuticals, Translational Sciences, Bayer AG, Berlin, Germany
| | - Sven Kronenberg
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Adam Hey
- Oncology Safety, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK
| | | | - Petra M. Schmitt
- Preclinical Safety, AbbVie Deutschland GmbH, Ludwigshafen, Germany
| | - Wouter Driessen
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Chantal Carrez
- Sanofi R&D, Translational In Vivo Models, Sanofi S.A, Vitry-sur-Seine, France
| | - Daniel Kramer
- Sanofi R&D, Translational Medicine & Early Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
| | | | - Wolfgang F. Richter
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Tobias Paehler
- Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
| | - Ulrike Hopfer
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Benno Rattel
- Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany
| |
Collapse
|
9
|
Catlin NR, Stethem CM, Bowman CJ, Campion SN, Nowland WS, Cappon GD. Knockout mouse models are predictive of malformations or embryo-fetal death in drug safety evaluations. Reprod Toxicol 2020; 96:11-16. [PMID: 32522587 DOI: 10.1016/j.reprotox.2020.06.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 05/11/2020] [Accepted: 06/01/2020] [Indexed: 10/24/2022]
Abstract
Traditionally, understanding potential developmental toxicity from pharmaceutical exposures has been based on the results of ICH guideline studies in two species. However, support is growing for the use of weight of evidence approaches when communicating the risk of developmental toxicity, where the intended pharmacologic mode of action affects fundamental pathways in developmental biology or phenotypic data from genetically modified animals may increasingly be included in the overall assessment. Since some concern surrounds the use of data from knockout (KO) mice to accurately predict the risk for pharmaceutical modulation of a target, a deeper understanding of the relevance and predictivity of adverse developmental effects in KO mice for pharmacological target modulation is needed. To this end, we compared the results of embryo-fetal development (EFD) studies for 86 drugs approved by the FDA from 2017 to 2019 that also had KO mouse data available in the public domain. These comparisons demonstrate that data from KO mouse models are overall highly predictive of malformations or embryo-fetal lethality (MEFL) from EFD studies, but less so of a negative outcome in EFD studies. This information supports the use of embryo-fetal toxicity data in KO models as part of weight of evidence approaches in the communication of developmental toxicity risk of pharmaceutical compounds.
Collapse
|
10
|
Hanson ML, Solomon KR, Van Der Kraak GJ, Brian RA. Effects of atrazine on fish, amphibians, and reptiles: update of the analysis based on quantitative weight of evidence. Crit Rev Toxicol 2020; 49:670-709. [DOI: 10.1080/10408444.2019.1701985] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Mark L. Hanson
- Department of Environment and Geography, University of Manitoba, Winnipeg, MB, Canada
| | - Keith R. Solomon
- School of Environmental Sciences, University of Guelph, Guelph, ON, Canada
| | | | | |
Collapse
|